Platinum Investment Management Ltd. Makes New $4.08 Million Investment in ProQR Therapeutics (NASDAQ:PRQR)

Platinum Investment Management Ltd. acquired a new stake in shares of ProQR Therapeutics (NASDAQ:PRQR - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,538,247 shares of the biopharmaceutical company's stock, valued at approximately $4,076,000. Platinum Investment Management Ltd. owned about 1.88% of ProQR Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of the company. Ballentine Partners LLC purchased a new stake in shares of ProQR Therapeutics during the 4th quarter valued at about $61,000. PNC Financial Services Group Inc. purchased a new stake in ProQR Therapeutics during the fourth quarter valued at approximately $77,000. OneDigital Investment Advisors LLC raised its position in ProQR Therapeutics by 37.0% in the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company's stock worth $105,000 after acquiring an additional 15,550 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of ProQR Therapeutics by 14.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company's stock worth $107,000 after acquiring an additional 7,300 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of ProQR Therapeutics during the 4th quarter valued at $260,000. Institutional investors own 32.65% of the company's stock.

Analysts Set New Price Targets

PRQR has been the topic of several recent research reports. HC Wainwright raised their price objective on ProQR Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a research note on Friday, March 14th. JMP Securities reissued a "market outperform" rating and issued a $8.00 price target on shares of ProQR Therapeutics in a report on Thursday, December 12th. Oppenheimer started coverage on shares of ProQR Therapeutics in a report on Friday, January 10th. They set an "outperform" rating and a $15.00 price objective for the company. Chardan Capital restated a "buy" rating and set a $4.00 target price on shares of ProQR Therapeutics in a research report on Friday, March 14th. Finally, Citigroup raised shares of ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 price objective for the company in a report on Monday, March 10th. One analyst has rated the stock with a sell rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $9.50.

Remove Ads

ProQR Therapeutics Stock Performance

Shares of NASDAQ:PRQR traded up $0.02 on Friday, reaching $1.65. The company's stock had a trading volume of 629,073 shares, compared to its average volume of 550,770. The company has a 50-day simple moving average of $2.16 and a 200 day simple moving average of $2.61. The company has a market cap of $134.77 million, a P/E ratio of -5.16 and a beta of 0.24. ProQR Therapeutics has a 52-week low of $1.59 and a 52-week high of $4.62.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).